

AD\_\_\_\_\_

Award Number: W81XWH-08-1-0652

TITLE: Molecular Mechanism of Lymph Node Metastasis in Breast Cancer

PRINCIPAL INVESTIGATOR: Rakesh K. Singh, Ph.D.

CONTRACTING ORGANIZATION: University of Nebraska  
Omaha, NE 68198

REPORT DATE: September 2009

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188		
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b>					
1. REPORT DATE (DD-MM-YYYY) 30/09/09		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 9/1/08-8/31/09	
4. TITLE AND SUBTITLE  Molecular Mechanism of Lymph Node Metastasis in Breast Cancer			5a. CONTRACT NUMBER <b>W81XWH-08-1-0652</b>		
			5b. GRANT NUMBER		
			5c. PROGRAM ELEMENT NUMBER		
6. AUTHOR(S)  Rakesh K. Singh, Ph.D. Go ckr"tulpi j B wpo eQf w			5d. PROJECT NUMBER		
			5e. TASK NUMBER		
			5f. WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  University of Nebraska Medical Center, 987835 Nebraska Medical Center, Omaha, NE 68198			8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)  U.S. Army Medical ResearchÁá^äÁRá\æã↔æ→ÁO~↑↑á^ä Ft. Detrick, MD 21702			10. SPONSOR/MONITOR'S ACRONYM(S)		
			11. SPONSOR/MONITOR'S REPORT NUMBER(S)		
12. DISTRIBUTION / AVAILABILITY STATEMENT  Approved for public release; distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Many challenges exist in the current management of metastatic breast cancer as there are fewer recognized therapeutic strategies. Therefore, a better understanding of the molecular events in the metastatic process is critical. Several reports have described correlation of hyaluronan (HA) with initiation and progression of various types of epithelial cancers. The HA synthase (HAS) isoforms encode the enzymes that produce and deposit HA while the hyaluronidase (HYAL) genes code for enzymes that degrade HA and their expression is dysregulated in various tumors as a result of transcriptional and epigenetic changes that accompany progression. In this report, we examined the expression of HAS1, HAS2 and HAS3, HYAL1 and HYAL2 and LYVE1 in mammary tumor cell with different metastatic potential (4T1, highly metastatic; Cl66, moderately metastatic; Cl66M2, low metastatic). We observed increased expression of HAS1, HAS2 and HAS3 as well as HAYL 1 and HAYL2 in aggressive mammary tumor cells. Next we stably knocked-down HAS2 and HAS3 expression and overexpressed LYVE1 in 4T1 cells and analyzed cell proliferation, migration, tumor growth and metastasis. We observed that Has2/Has3 knock-down and LYVE1 overexpression modulated mammry tumor growth and spontaneous metastasis. Together, these data demonstrate an important role of HAS2 and LYVE1 in mammary tumor growth, angiogenesis, invasion, and metastasis.					
15. SUBJECT TERMS Hyaluronan Synthase, Tumor Growth, Metastasis, Breast Cancer					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES  5	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			19b. TELEPHONE NUMBER (include area code)

## Progress Report

Lymph node metastasis represents one of the first steps in breast cancer metastasis. At the time of diagnosis, majority of breast cancer patients have developed lymph node (LN) metastases, which is an important prognostic indicator. The mechanism(s) regulating lymphatic invasion and metastasis in breast cancer are currently unknown. A better understanding of the biology of malignant cells and lymphatics in LN metastasis has important therapeutic implications in breast cancer.

**Objective/Hypothesis:** The lymphatics, an extensive network of vessels, play a key role in immune surveillance, transport and recirculation of extracellular matrix (ECM) components such as hyaluronan (HA) from the interstitial fluid. The transport of HA through lymphatics is exciting, as this glycosaminoglycan has already been implicated as substrate for both leukocyte migration and tumor dissemination. Malignant cells produce and shed HA into ECM and a higher level of HA in the tumor interstitium predicts poor survival of breast cancer patients, possibly because of enhanced invasion/metastasis. Recent studies have identified a specific HA receptor, LYVE-1, primarily on lymph endothelial cells (LEC). Sequestration of HA through interaction with LYVE-1 facilitates HA transport and degradation within the lymphatics. Exploitation of this physiological pathway may provide a conduit for malignant tumor cells to metastasize to LN. Recent studies suggest that HA-LYVE-1 interaction could allow up-regulation of secondary lymphoid tissue-chemokine (SLC/CCL21), a chemokine that induces migration of inflammatory leukocytes to lymph nodes. CXCL21 is primarily expressed in LECs and functions as a chemoattractant for CCR7-expressing dendritic cells and T cells. We hypothesize that exploitation of HA-LYVE-1 interactions by breast cancer cells allows their preferential LN metastasis mediated by CXCL21. In this current proposal, we will test this unique concept which will provide an insight into interactions of breast cancer cells with LECs, their translocation through LECs and establishment as LN metastasis. In this Concept Award application, we will test the hypothesis that HA-LYVE-1 interaction resulting in LEC production of CXCL21 regulates LN metastasis in breast cancer. Two specific aims are proposed.

### **Specific Aims:**

- 1) Test the hypothesis that expression of HA and LYVE-1 on breast cancer cells and LECs and their interaction regulate LN metastasis.
- 2) Test the hypothesis that binding of HA to LYVE-1 regulates SLC production in LECs, which functions as chemoattractant for CCR7-expressing breast cancer cells.


### **Results.**

#### **1) Test the hypothesis that expression of HA and LYVE-1 on breast cancer cells and LECs and their interaction regulate LN metastasis.**

1. We analyzed the basal expression of LYVE1 and HA and Has1, Has2, and Has3. 4T1 cells express high levels of Has1 and Has2 and HA. We did not observe LYVE1 expression in 4T1 cells.

2. We stably transfected 4T1 cells with mammalian expression vector containing LYVE1 cDNA to generate stable LYVE1 expressing 4T1 cells. We analyzed expression of LYVE and *in vitro* phenotypes of these cells. LYVE1 expressing cells showed growth advantage at lower serum concentrations as compared to control vector transfected cells.

Figure 1. Cellular morphology and *in vitro* cell proliferation.




We observed a morphological distinction in 4T1-LYVE1 cells (**Figure 1**).

3. We transfected 4T1 cells with shRNA vector targeting Has2 and Has3 expression. Following selection to derive stable clones, cells were examined for Has2, Has3 and HA expression using realtime RT-PCR.
4. 4T1-LYVE1 and 4T1 control vector cells were injected into mammary fat pad of BALB/c mice and tumor growth and metastasis was monitored.

We observed enhanced tumor growth and spontaneous lung metastasis in animals injected with 4T1-LYVE1 cells as compared to 4T1-control cells (**Figure 2**). These data suggest that ectopic expression of LYVE1

**Figure 2. Enhanced Tumor Growth and Spontaneous Lung Metastasis in LYVE1 Expression Mammary Tumor Cells.**



enhanced tumor growth and metastatic potential in mammary tumor cells.


**2). Has2 and Has3 Expression in Mammary Tumor Cells Modulates Tumor Growth Angiogenesis and Metastasis.** Several reports have described correlation of hyaluronan (HA) with initiation and progression of various types of epithelial cancers. The HA synthase (HAS) isoforms encode the enzymes that produce and deposit HA while the hyaluronidase (HYAL) genes code for enzymes that degrade HA and their expression is dysregulated in various tumors as a result of transcriptional and epigenetic changes that accompany progression. In this report, we examined the expression of HAS1, HAS2 and HAS3, HYAL1 and HYAL2 in mammary tumor cell with different metastatic potential (4T1, highly metastatic; Cl66, moderately metastatic; Cl66M2, low metastatic). We observed increased expression of HAS1, HAS2 and HAS3 as well as HAYL 1 and HAYL2 in aggressive mammary tumor cells. Next we stably knocked-down HAS2 and HAS3 expression in 4T1 cells using small hairpin mRNA (sh-RNA) vectors and analyzed cell proliferation, migration, tumor growth and metastasis. We observed inhibition of *in vitro* cell proliferation and migration in 4T1 cells knocked-down for HAS2 (4T1-HAS2sh) and HAS3 (4T1-HAS3sh) as compared to cells transfected with vector control (4T1-controlsh). Furthermore, we observed inhibition of *in vivo* tumor growth and spontaneous lymph node and lung metastases in animals implanted with 4T1-HAS2sh cells as compared to 4T1-controlsh (**Figure 3**). In addition, we observed inhibition of tumor cell proliferation and neovascularization, and increased apoptosis in 4T1-shHAS2 tumors as compared to 4T1-controlsh tumors. Together, these data demonstrate an important role of HAS2 in mammary tumor growth, angiogenesis, invasion, and metastasis.

**On-going Experiments: Test the hypothesis that binding of HA to LYVE-1 regulates SLC production in LECs, which functions as chemoattractant for CCR7-expressing breast cancer cells. (Months 1-12)**

Generation of 4T1 cells expressing different levels of CCR7 by stable transfection of shRNA targeting CCR7.

Determine the effect of hyaluronan on lymph endothelial cell CXCL21 production.  
Determine the effect of CXCL21 on tumor cell (expressing different levels of Has2, Has3 and LYVE1) chemotaxis.

**Figure 3. Inhibition of Tumor Growth and Spontaneous Lung Metastasis in Has2 and Has3 knockdown Mammary Tumor Cells.**



**Relevance:** These studies will provide unique insights into a causal relationship between HA-LYVE-1 and SLC-mediated regulation of LN metastasis in breast cancer. The knowledge gained from these studies will provide a foundation to develop diagnostic markers and novel therapeutics to inhibit early LN metastasis in breast cancer.

**Publication: Abstract:**

Varney ML, Nannuru KC, and **Singh RK**. Hyaluronan Synthase Expression in Mammary Tumor Cells Modulates Tumor Growth Angiogenesis and Metastasis. Annual Meeting of American Association for Cancer Research 2010.